Avalo Therapeutics (AVTX) Interest & Investment Income (2014 - 2026)
Avalo Therapeutics posted quarterly Interest & Investment Income of $803000.0 for Q1 2026, down 30.05% year-on-year from $1.1 million in Q1 2025, and down 18.39% on a QoQ basis from $984000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Interest & Investment Income data on file, last reported at $803000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 30.05% year-over-year to $803000.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 8.16% YoY), and the FY2025 full-year result was $4.4 million, up 31.37% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $803000.0, down from $984000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.2 million in Q4 2024 and bottomed at -$1.6 million in Q3 2023.
- The 5-year median for Interest & Investment Income is $100000.0 (2024), against an average of $51823.5.
- The widest annual swing landed in 2022, when Interest & Investment Income plunged 6976.47%; it then soared 1395.06% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at -$949000.0 in 2022, then soared by 108.54% to $81000.0 in 2023, then jumped by 1395.06% to $1.2 million in 2024, then retreated by 18.74% to $984000.0 in 2025, then decreased by 18.39% to $803000.0 in 2026.
- The last three Interest & Investment Income figures came in at $803000.0 (Q1 2026), $984000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 803,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 803,000.00 |
| Dec 31, 2025 | 984,000.00 |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 964,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -996,000.00 |
| Mar 31, 2023 | -949,000.00 |
| Dec 31, 2022 | -949,000.00 |
| Sep 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -1.15 Mn |
| Mar 31, 2022 | -1.17 Mn |
| Dec 31, 2021 | -1.18 Mn |
| Sep 30, 2021 | -985,000.00 |
| Jun 30, 2021 | -239,000.00 |
| Mar 31, 2021 | 17,000.00 |
| Dec 31, 2020 | 49,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Dec 31, 2019 | 734,950.00 |
| Sep 30, 2019 | -205,938.00 |
| Jun 30, 2019 | 38,412.00 |
| Mar 31, 2019 | 30,217.00 |
| Dec 31, 2018 | 593,925.00 |
| Sep 30, 2018 | -234,854.00 |
| Jun 30, 2018 | -242,407.00 |
| Mar 31, 2018 | -100,402.00 |
| Dec 31, 2017 | 31,000.00 |
| Sep 30, 2017 | 29,387.00 |
| Jun 30, 2017 | -25,631.00 |
| Mar 31, 2017 | -57,748.00 |
| Dec 31, 2016 | -83,000.00 |
| Sep 30, 2016 | -104,000.00 |
| Jun 30, 2016 | -127,000.00 |
| Mar 31, 2016 | -151,000.00 |
| Dec 31, 2015 | -158,000.00 |
| Sep 30, 2015 | -197,000.00 |
| Jun 30, 2015 | -219,000.00 |
| Mar 31, 2015 | -219,000.00 |
| Dec 31, 2014 | -221,000.00 |
| Sep 30, 2014 | -190,000.00 |